LIBTAYO 350 MG CONCENTRADO PARA SOLUCION PARA PERFUSION

( ARTG ) Cutaneous Squamous Cell Carcinoma,LIBTAYO as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation.Non-Small Cell Lung Cancer,LIBTAYO as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 tumour proportion score (TPS) greater than and equal to 50% as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have:, locally advanced NSCLC and who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.,LIBTAYO in combination with platinum-based chemotherapy is indicated for the first-line treatment of patients with NSCLC whose tumours have no EGFR, ALK or ROS1 aberrations and is:, locally advanced where patients are not candidates for surgical resection or definitive chemoradiation, or, metastatic.Basal Cell Carcinoma,LIBTAYO as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate.